CHRNA7 and Alzheimer disease: Sumifilam (PTI-125) could stabilize the interaction of soluble Aβ and the α7-nicotinic acetylcholine receptor (α7nAChR) to prevent toxic signaling of Aβ, which improved multiple biomarkers of AD in phase 2 studies [84].